Expect New PCSK9 Inhibitors to be Saved as Statin Add-Ons

You'll hear buzz about the "PCSK9 inhibitors" for high cholesterol, Praluent (PRAL-you-ent, alirocumab) and Repatha (ree-PATH-ah, evolocumab).

Health Canada will probably consider these for approval within the next year. Praluent has recently been approved in the U.S...and Repatha will soon follow.

These monoclonal antibodies will be the first biologics injected subcutaneously once or twice a MONTH for high LDL cholesterol.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote